Global HIV-associated Lipodystrophy Market - 2023-2030

Global HIV-associated Lipodystrophy Market - 2023-2030

Global HIV-associated Lipodystrophy Market reached US$ 174.90 million in 2022 and is expected to reach US$ 228.11 million by 2030, growing with a CAGR of 3.4% during the forecast period 2023-2030.

Lipodystrophy refers to the transformations in body fat that can impact some individuals with HIV. Lipodystrophy can have a buildup of body fat, loss of body fat, or both. Lipodystrophy may be owing to HIV infection or drugs utilized for the treatment of HIV, but its exact reason is not comprehended. The most recent HIV drugs are less likely to induce lipodystrophy compared to HIV medications designed in the past.

Lipodystrophy is not a problem for a majority of individuals who begin HIV therapy currently, because newer HIV medicines are less likely to cause lipodystrophy. The syndrome constitutes two different clinical indications that can occasionally emerge concurrently. Several therapy alternatives have been specified to aid in reducing the morbidity patients may encounter due to this disorder.

The growing cases of HIV infections, increasing initiatives to spread awareness, and support efforts among other factors are expected to boost the global HIV-associated lipodystrophy market growth during the forecast period. Further, increasing research activities and HIV research funding are expected to contribute to the global HIV-associated lipodystrophy market growth during the forecast period.

Dynamics

The Growing Prevalence of HIV Drive the Market Growth

The preponderance of HALS rises with expanded periods of exposure to highly active antiretroviral therapy (HAART) and is registered to be present in around 50% of individuals on antiviral therapy. However, the exact prevalence of HIV-associated lipodystrophy has been challenging to establish due to differences in case definition, but estimates range from 10% to 80% among all people living with HIV worldwide. Thus, the growing cases of HIV infection are estimated to boost the global HIV-associated lipodystrophy market growth during the forecast period.

For instance, according to the UNAIDS, a Joint United Nations Programme on HIV and AIDS, in 2022over 39.0 million individuals worldwide were living with HIV, more than 1.3 million individuals were newly infected with HIV and around 630 000 individuals died because of AIDS-related ailments. Moreover, according to the same source about 29.8 million individuals with AIDS were accessing antiretroviral therapy in 2022, and a sum of 85.6 million individuals were infected with HIV causing 40.4 million deaths from AIDS-related illnesses since the beginning of the epidemic.

Increasing Number of Initiatives to Fight Against HIV Burden

The increasing initiatives from governments to fight the growing burden of HIV infection cases and associated deaths are also contributing to the global market growth. For instnace, in May 2023, the National HIV/AIDS Strategy and the Ending the HIV Epidemic in the U.S. Initiative emphasized detecting people as shortly as possible and confirming the availability of considerable HIV testing modalities to sufficiently satisfy the requirements of inhabitants with an improved chance of transmission owing to a broad spectrum of social, economic, and demographic aspects including stigma, discrimination, etc.

Again, since the research exhibits that a steady residence is essential to the well-being of individuals living with HIV/AIDS, and influences better health effects and decreased transmission of the infection, the U.S. Department of Housing and Urban Development’s (HUD) Office of HIV/AIDS Housing declared it over $13 million in Housing Opportunities for people with AIDS (HOPWA) Permanent Supportive Housing (PSH) Renewal and Replacement Grants, which aid with tenant-based rental service, substantiating assistance, and additional accommodation activities in December 2022.

Large Expenses of HIV-Associated Lipodystrophy Therapy

The large expenses of HIV-associated lipodystrophy therapy is expected to hamper HIV-associated Lipodystrophy market growth in the forecast period. For instance, the Sculptra(injectable poly-L-lactic acid, New-Fill) therapy is the foremost facial filler authorized in the US for HIV-related lipoatrophy which costs roughly $500 to $1000 per vial in the US excluding fees for anesthesia or the surgical facility. Radiesse (calcium hydroxylapatite) is also FDA-approved for facial lipoatrophy in individuals living with HIV.

Radiesse includes synthetic calcium hydroxylapatite, a substance discovered in bones and teeth that promotes the body's production of collagen, the therapy costs approximately $600 to $800 per vial in the US. Similarly, the autologous fat transplant procedure also anointed 'fat-grafting' or fat transfer, costs several thousand dollars and the collagen (CosmoDerm, CosmoPlast) cost per treatment in the US varies from $300-$900, and therapies last for three to six months, requiring repetative session.

Gaps in HIV Anti Retroviral Therapy

The gaps in HIV ART therapy are also expected to slow the global market growth during the forecast period. For instnace, in 2015, the World Health Organization (WHO) modified multinational HIV policies and approved a “Treat All” policy, which withdrew CD4-based clinical staging measures for antiretroviral therapy (ART) initiation and extended ART eligibility for children.

While, the “Treat All” policy called for raised equity in HIV therapy, between 2010 and 2020, the pediatric ART range increased threefold, leaping from 16% to 54%. However, pediatric coverage yet invariably crawled after adult ART coverage, which leaped from 26% in 2010 to 74% in 2020. Meanwhile, AIDS-related casualties fell by over half, going from 240,000 to 99,000 over a period of 10 years.

Segment Analysis

The global HIV-associated lipodystrophy market is segmented based on type, route of administration, distribution channel and region.

The Drug Treatment Type is Expected to Dominate the Market

The availability of specific drug treatment for HIV-associated lipodystrophy and the growing prevalence of diabetes cases in HIV-infected patients are expected to boost the segment growth in the forecast period. For instance, EGRIFTA SV is an FDA-authorized injectable prescription medicine utilized to lower extra abdominal fat in adult individuals living with HIV and lipodystrophy. EGRIFTA SV is a growth hormone-releasing factor (GHRF) analog.

Moreover, according to Georgia University, Diabetes mellitus is one of the chronic comorbidities found in individuals with HIV. Studies have reported changes in glucose homeostasis or fat redistribution in HIV-infected patients. Identified risk factors associated with the development of diabetes in pers ns without HIV are the same as those in PLWHIV, including higher triglyceride, older age, obesity, genetics, and hypertension. Further, HIV and some HAART medicines may also increase the chance of acquiring diabetes or developing it at a younger age. A 2021 investigation assesses that over 15 percent of individuals with HIV have diabetes.

Geographical Penetration

Increasing Number of HIV Infections Cases in North America

Owing to the increasing number of HIV infections, government funding, and awareness initiatives are boosting the regional market growth during the forecast period. For instance, a fresh investigation from the Centers for Disease Control and Prevention demonstrates that the number of individuals obtaining lifesaving HIV therapy via PEPFAR has risen 300-fold in just 20 years, from 2004 to 2022. The statistics of individuals obtaining HIV antiretroviral therapy (ART) via PEPFAR grew from merely 66,500 people in 2004, the year after PEPFAR was introduced, to over 20 million individuals in 2022.

Further, in April 2023, the Health Resources and Services Administration (HRSA), an association of the U.S. Department of Health and Human Services (HHS), rewarded over $147 million to 49 recipients to extend the Ending the HIV Epidemic in the U.S. (EHE) initiative, which is an aspect of the Biden-Harris Administration’s continued measures to decrease the number of recent HIV infections in the United States by at least 90% by 2030. This funding is expected to support states and metropolitan areas with the highest levels of HIV transmission to link individuals with HIV to elementary care, aid, therapy, asset training, and other aids for these jurisdictions.

Also, the Southern HIV/AIDS Awareness Day (SHAAD) is a day that people, societies, and associations can join to summon awareness of the disproportionate number of individuals living with HIV in the South. SHAAD is a chance to deliver individuals in the South with HIV testing and connection to HIV medical care if required, instruction on HIV prevention, including methods to stop HIV stigma and other HIV-related care aids.

COVID-19 Impact Analysis

The pandemic disturbed the global healthcare system with disturbances in diagnosis, treatments, and research activities for other conditions which negatively impacted the overall healthcare market growth including HIV-associated lipodystrophy. However, as HIV-associated lipodystrophy was believed to be among the post-COVID-19 complications leading increase in diagnosis and treatment demands having a positive impact on the market growth.

Testing is the foremost method to learn if a person has been infected with SARS-CoV-2. Individuals with HIV were advised to instantly reach their healthcare provider if they tested positive for COVID-19. Individuals with HIV were suggested to persist in taking their HIV medications as specified. The Centers for Disease Control and Prevention (CDC) advised that individuals with HIV who were qualified should get a COVID-19 vaccine primary dose (also known as the initial dose), and a booster dose, regardless of viral burden or CD4 T lymphocyte cell count. Thus, the pandemic is estimated to hold an intermediate impact over the global market.

By Type
• Drug Treatment
Anabolism Modulators
Growth Hormones
Anabolic Steroids
Metformin
Thiazolidinediones
Others
• Cosmetic Corrective Treatment
Lipotherapy
Lipoaccumulation
Dermal Fillers
Autologous Fat Transplant
Other

By Route of Administration
• Oral
• Injectables
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In August 2022, the European Commission authorized lenacapavir for treatment-experienced individuals with multidrug-resistant HIV who cannot otherwise create a thoroughly suppressive regimen.
• In August 2023, global pharma major Lupin Limited acquired the diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim, including the trademark rights associated with these brands.

Competitive Landscape

The major global players in the market include Theratechnologies Inc., Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, AbbVie, Galderma Laboratories, L.P. and GlaxoSmithKline among others.

Why Purchase the Report?
• To visualize the global HIV-associated lipodystrophy market segmentation based on type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of HIV-associated lipodystrophy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The global HIV-associated lipodystrophy market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies